Suppr超能文献

巨细胞病毒决定簇对 CD8 T 细胞编程和 RhCMV/SIV 疫苗效力的影响。

Cytomegaloviral determinants of CD8 T cell programming and RhCMV/SIV vaccine efficacy.

机构信息

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21702, USA.

出版信息

Sci Immunol. 2021 Mar 25;6(57). doi: 10.1126/sciimmunol.abg5413.

Abstract

Simian immunodeficiency virus (SIV) insert-expressing, 68-1 rhesus cytomegalovirus (RhCMV/SIV) vectors elicit major histocompatibility complex E (MHC-E)- and MHC-II-restricted, SIV-specific CD8 T cell responses, but the basis of these unconventional responses and their contribution to demonstrated vaccine efficacy against SIV challenge in the rhesus monkeys (RMs) have not been characterized. We show that these unconventional responses resulted from a chance genetic rearrangement in 68-1 RhCMV that abrogated the function of eight distinct immunomodulatory gene products encoded in two RhCMV genomic regions ( and ), revealing three patterns of unconventional response inhibition. Differential repair of these genes with either RhCMV-derived or orthologous human CMV (HCMV)-derived sequences (; ) leads to either of two distinct CD8 T cell response types-MHC-Ia-restricted only or a mix of MHC-II- and MHC-Ia-restricted CD8 T cells. Response magnitude and functional differentiation are similar to RhCMV 68-1, but neither alternative response type mediated protection against SIV challenge. These findings implicate MHC-E-restricted CD8 T cell responses as mediators of anti-SIV efficacy and indicate that translation of RhCMV/SIV vector efficacy to humans will likely require deletion of all genes that inhibit these responses from the HCMV/HIV vector.

摘要

猿猴免疫缺陷病毒(SIV)插入表达、68-1 恒河猴巨细胞病毒(RhCMV/SIV)载体引发主要组织相容性复合体 E(MHC-E)和 MHC-II 限制的、SIV 特异性的 CD8 T 细胞反应,但这些非常规反应的基础及其对恒河猴(RMs)中 SIV 挑战显示的疫苗效力的贡献尚未得到表征。我们表明,这些非常规反应源自 68-1 RhCMV 中的偶然遗传重排,该重排削弱了两个 RhCMV 基因组区域(和)中编码的八个不同免疫调节基因产物的功能,揭示了三种非常规反应抑制模式。这些基因的差异修复与 RhCMV 衍生或同源人巨细胞病毒(HCMV)衍生序列(;)导致两种不同的 CD8 T 细胞反应类型之一-MHC-Ia 限制或 MHC-II 和 MHC-Ia 限制的 CD8 T 细胞的混合物。反应幅度和功能分化与 RhCMV 68-1 相似,但两种替代反应类型都不能介导对 SIV 挑战的保护。这些发现表明 MHC-E 限制的 CD8 T 细胞反应是抗 SIV 疗效的介导者,并表明 RhCMV/SIV 载体疗效向人类的转化可能需要从 HCMV/HIV 载体中删除所有抑制这些反应的基因。

相似文献

4
Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy.白细胞介素-15 反应特征可预测 RhCMV/SIV 疫苗的疗效。
PLoS Pathog. 2021 Jul 6;17(7):e1009278. doi: 10.1371/journal.ppat.1009278. eCollection 2021 Jul.

引用本文的文献

本文引用的文献

5
..
Vaccines (Basel). 2019 Jul 22;7(3):70. doi: 10.3390/vaccines7030070.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验